कृपया अन्य खोज का प्रयास करें
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Craig Eagle | 56 | 2021 | Independent Director |
Christopher C. Chapman | 70 | 2020 | President, Chief Medical Officer & Director |
Joshua N. Silverman | 53 | 2018 | Independent Chairman of the Board |
Jeremy D. Walston | - | - | Member of Scientific Advisory Board |
Billy Joe White | 62 | 2017 | Independent Director |
Jude C. Uzonwanne | 49 | 2021 | Independent Director |
Christopher C. Schreiber | 58 | 2017 | Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है